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Abstract  
 
Purpose of review: Although the cholinergic hypothesis of dementia provided a 
successful paradigm for the development of new drugs for dementia, this 
hypothesis has waned in popularity. Cholinergic brain imaging may provide novel 
insights into the viability of this hypothesis.  
 
Recent findings: Cholinergic receptor and forebrain volumetric studies suggest 
an important role of the cholinergic system in maintaining brain network integrity 
that may deteriorate with cognitive decline in Alzheimer disease (AD) and Lewy 
body disorders (LBD). Bidirectional changes in regional receptor expression may 
suggest the presence of compensatory responses to neurodegenerative injury.  
Cholinergic system changes are more complex in LBD because of additional 
subcortical degenerations compared to AD. Cholinergic-dopaminergic interactions 
affect attentional, verbal learning and executive functions and impairments in these 
two transmitter systems may jointly increase the risk of dementia in Parkinson 
disease. 
 
Summary: The cholinergic hypothesis is evolving from a primary focus on memory 
toward expanded cognitive functions modulated by regionally more complex and 
interactive brain networks. Cholinergic network adaptation may serve as a novel 
research target in neurodegeneration.  
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Introduction 
 
 Current insights point to a multisystem etiology of cognitive impairment and 
memory loss in dementing disorders. Early studies, however, advocated the so-
called 'cholinergic hypothesis' to explain cognitive and memory deficits in 
Alzheimer disease (AD) [1, 2]. This hypothesis resulted from observations of 
prominent cholinergic cell loss in the nucleus basalis of Meynert (NBM) in AD post-
mortem brains [3, 4]. Significant loss of cholinergic forebrain neurons has also 
been reported in Parkinson disease (PD) brains [5]. Arendt et al. found even 
greater forebrain neuronal loss in PD than in AD [6], suggesting that cholinergic 
deficits may be at least as prominent in PD as in AD. More recent neuroscience 
research confirms the vital role of cholinergic neurotransmission in cognitive 
function, specifically in attention and memory encoding [7].   
 The cholinergic hypothesis provided a successful paradigm for the 
successful approval of cholinesterase inhibitors as a treatment for AD and later 
parkinsonian dementia. However, despite these advances and over four decades 
of research, the cholinergic hypothesis has lost some interest, in large part 
because of the limited effectiveness of cholinesterase inhibitor drugs in clinical 
practice [8] and the advance of new in vivo PET imaging radiotracers which 
highlight the role of β-amyloid, and more recently, tau proteinopathies in memory 
loss, at least in AD. 
 The goal of this review is provide an update on the recent cholinergic 
neuroimaging literature in an attempt to highlight and clarify the role of the 
cholinergic system in cognitive impairment in the two major neurodegenerative 
disorders: AD and Lewy body disorders (LBD).  
 
Imaging biomarkers and cognition 
 
 Imaging biomarkers of cognition are complex and include markers of a) 
proteinopathy, such as β-amyloidopathy, tauopathy or α-syncleinopathy, b) 
neurodegeneration, including neuronal loss and axonal degeneration, c) 
neurotransmission and d) abnormalities of brain function and connectivity [9]. 
Proteinopathy and other changes in subcortical projection systems may result in 
neurotransmitter changes [10], including cholinergic and dopaminergic systems. 
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Neurotransmitter changes are particularly important in the setting of fluctuating 
cognitive symptoms. Molecular imaging methods, such as positron emission 
tomography (PET) or single photon computed tomography (SPECT) imaging 
studies allow assessment of the cholinergic neurotransmission system in the living 
brain. Magnetic resonance imaging (MRI) plays an important role in volumetric 
assessment of the cholinergic substantia innominate containing the NBM. 
 Multi-modal imaging approaches will be of particular importance to study a 
more specific relationship between changes in cholinergic markers and cognition 
by controlling for important cognitive disease confounders, such as the presence 
of β-amyloid plaques or dopaminergic degenerations. 
 
Cholinergic anatomy and in vivo imaging ligand targets 
 
 There are several sources of cholinergic projections in the brain. 
Magnocellular neurons of the cholinergic basal forebrain (CBFB) provide 
widespread cholinergic input to the telencephalon [11]. Cholinergic neurons of the 
medial septal nucleus (also known as the Ch1 cell group) and the vertical limb 
nucleus of the diagonal band (Ch2) provide the major cholinergic input of the 
hippocampus; cholinergic neurons of the horizontal limb nucleus of the diagonal 
band (Ch3) provide the major cholinergic input of the olfactory bulb; and cholinergic 
neurons of the NBM (or Ch4) provide the principal cholinergic input of the 
remaining cerebral cortex and amygdala [12]. The PPN, ulopontine nucleus (Ch5 
cell group) and laterodorsal tegmental complex (LDTC, Ch6 cell group) supply 
cholinergic inputs to the cerebellum, several brainstem nuclei, thalamus, spinal 
cord and some striatal fibers [13, 14]. The basal ganglia also contain a population 
of cholinergic interneurons [15, 16]. 
 Several cholinergic markers have been labeled for PET or SPECT 
molecular imaging. Acetylcholinesterase (AChE) has been recognized since 1966 
as a reliable marker for brain cholinergic pathways including in the human brain 
[17]. The vesicular acetylcholine transporter (VAChT) is a more pure marker of 
presynaptic cholinergic terminal density. [123I]IBVM and [18F]FEOBV are SPECT 
and PET VAChT ligands, respectively. [11IC]PMP and [11C]MP4A are PET AChE 
ligands. Both AChE and VACHT ligands can be used to study the integrity of 
presynaptic cholinergic nerve terminals. Several radiotracers have also been 
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developed for labeling of nicotinic and muscarinic cholinergic receptors. For 
example, [123I]5IA and [18F]flubatine are α4β2 nicotinic acetylcholine receptor 
(nAChR) SPECT and PET ligands, respectively. [123I]QNB is a SPECT ligand to 
visualize muscarinic  M1/M4 receptors (mAChR).    
 
Cholinergic nerve terminal integrity imaging 
 
Normal aging, mild cognitive impairment and Alzheimer disease 
 
 Early in vivo cholinergic PET and SPECT neuroimaging studies have 
confirmed post-mortem observations of cholinergic losses in AD. For example, 
cholinergic nerve terminal imaging studies have shown reduced cortical VAChT 
and AChE binding in AD compared to control subjects [18-20]. Thalamic AChE 
activity is generally spared in AD [21]. These cholinergic losses affect cognitive 
performance, not only in AD but also in healthy aging. For example, a [11C]MP4A 
AChE PET study in healthy elderly reported that the integrity of the cholinergic 
system in the mesiotemporal region associated with verbal episodic memory 
delayed recall performance in healthy elderly [22]. The number of words forgotten 
after a 30 min delay period negatively correlated with AChE activity in the right 
posterior cingulate cortex, and frontal regions. A [11C]MP4A AChE PET study in 
patients with mild cognitive impairment (MCI) found three clusters of reduced 
AChE activity compared to normal subjects: fronto-parietal, lateral temporal and 
limbic (hippocampal/amygdala) clusters [23]. AChE reductions were most 
prominent in the lateral temporal cluster that correlated significantly with learning, 
executive and language comprehension functions. We previously reported that 
reduced cortical AChE associated with attentional and working memory deficits in 
AD [24]. A recent VAChT PET study in AD patients using the [18F]FEOBV ligand 
found evidence of reduced cortical transporters with greatest reductions in the 
superior and middle temporal cortex extending in the inferior parietal lobule [25]. 
Severe reductions were observed also in the posterior medial cortical territory, 
including the posterior cingulate cortex and the precuneus. Frontal reductions, 
however, were less prominent. This pattern agrees with topographic findings, 
which suggest a caudal-rostral pattern of degeneration of the CBFB the AD brain 
[26]. The degree of regional FEOBV uptake reductions in patients with AD was 
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highly variable among the different areas, ranging from 8.9% in the anterior 
cingulate, to 51% in the superior temporal gyrus. Cortical transporter uptake 
correlated robustly with global cognition in the patients [25]. No significant 
differences between AD patients and control subjects were found in the 
hippocampus, thalamus, striatum or cerebellum [25].  These observations indicate 
that septal nuclei and substantia innominata, the proposed origins of the 
cholinergic projections to the hippocampus and neocortex, respectively, are 
differentially involved in AD.  
 
Lewy body disorders 
 
 According to the Braak staging scheme of PD pathology, α-synuclein-
positive inclusions in the basal cholinergic forebrain areas simultaneously occur 
with nigral pathology in the early stage of PD [27]. There are more severe 
cholinergic losses in parkinsonian dementia compared to AD of similar degree of 
cognitive impairment [28]. As a consequence, there is a relatively greater clinical 
response to AChE inhibitor drugs in patients with LBD than AD [29]. As reductions 
in cholinergic nerve terminal integrity are consistently more severe in PD dementia 
than in PD, cholinergic dysfunction may be responsible for the transition from PD 
to PD with dementia [30]. 
 A recent VAChT [123I]IBVM SPECT study investigated the integrity of the 
three major cholinergic pathways - the Ch1 (septohippocampal), the Ch4 
(innominatocortical), the Ch5 (pontothalamic) cholinergic pathways and striatal 
cholinergic interneurons in patients with dementia with Lewy bodies (DLB) [31]. 
Compared to healthy subjects, VAChT binding values for DLB patients were 
significantly lower in the Ch4 terminal regions of the anterior cingulate cortex (-
59%), the superior (-78%) and inferior parietal cortices (-47%), in the Ch5 terminal 
region of the thalamus (-69%), and in the striatum (-45%). No significant reductions 
were seen for the hippocampus (Ch1 terminal region) illustrating differential 
degeneration of CBFB regions. 
 
Cholinergic and dopaminergic interactive effects and cognition in PD: The 
'compensatory' hypothesis 
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 We recently reported heterogeneity in both cortical and subcortical 
(thalamic) AChE hydrolysis rates in PD patients in the absence of dementia [32].  
About one third of PD patients (31%) had below normal range neocortical 
acetylcholinesterase activity and about one sixth (18%) had below normal range 
thalamic acetylcholinesterase activity. Most patients with thalamic cholinergic 
hypofunction also had reduced cortical cholinergic activity implying a possible 
sequence effect where cholinergic losses in the forebrain NBM may precede PPN-
thalamic losses. We found that cortical cholinergic activity inversely correlated with 
verbal learning, executive and attentional functions independent from 
dopaminergic losses [32, 33]. Furthermore, we found that cortical cholinergic and 
caudate nucleus dopaminergic denervation not only had additive but also 
interactive effects in their prediction of cognitive impairment in PD [33]. 
Interestingly, interactive or multiplicative effects were most significant for executive 
function deficits. Therefore, it is conceivable that loss of cholinergic nerve terminals 
may worsen fronto-striatal dysfunction due to loss of compensatory attentional 
resources [34]. As executive function impairments are a strong predictor for 
conversion to dementia [35], these findings may explain why cholinergic losses are 
consistently seen in PD dementia. Conversely, we found that that a substantial 
proportion of patients with no apparent cognitive deficits, including on executive 
tasks, nevertheless had significant dopaminergic denervation in the setting of 
preserved cholinergic activity. These observation formed the basis for the 
'compensatory' hypothesis [33] as also suggested by animal lesioning studies [36]: 
Fronto-parietal cortical cholinergic functions associated with top-down control may 
be recruited (increased cholinergic activity in cortical circuits) to compensate for 
executive dysfunctions associated with striatal dopaminergic declines, and vice 
versa. Furthermore, we found that cholinergic changes have incremental 
contributions to cognitive decline not only independent from dopaminergic losses 
but also from cognitive effects of β-amyloid plaques in PD at risk of dementia [37].  
 
Thalamic cholinergic denervation and saliency bottom-up processing in PD 
 
 We explored cognitive correlates of thalamic (subcortical) cholinergic 
hypofunction in PD patients and found evidence of a specific contribution to 
bottom-up saliency processing [38]. Attention can be focused volitionally by "top-
   9 
down" signals derived from task demands and automatically by "bottom-up" 
signals from salient stimuli [39]. Saliency detection is considered a key attentional 
mechanism that facilitates learning by focusing limited perceptual and 
cognitive resources on the most pertinent subset of the available sensory data. We 
found that thalamic cholinergic integrity predicted signal detection under 
perceptual challenge in PD [38]. The specific association with hits, and lack of 
relationship to correct rejections, supports the idea that the thalamic contributions 
are related to bottom-up signal salience, rather than top-down control of attentional 
selection. These results suggest that there are regionally-specific contributions of 
cholinergic function to different aspects of attention and behavior. 
 
 
Cholinergic receptor imaging: Exploring brain networks  
 
 The previous discussed studies have examined region-specific effects of 
cholinergic denervation on cognition. However, to truly understand the effects of 
impaired cholinergic transmission on cognition it should be studied in the context 
of the larger networks that these specific regions encompass. Recent insights from 
neuroscience research have begun to unravel the heterogeneous involvement of 
several distinct neural networks underlying the cognitive deficits in dementia, and 
their modulation by neurotransmitter systems in the brain [40]. To this end, several 
studies have proposed network analyses of the cholinergic receptors.  Cholinergic 
neurotransmission in the brain is mediated by ionotropic nAChR and metabotropic 
mAChR receptors. Previous α4β2 nAChR studies have found significant 
correlations between reduced receptor binding and cognition in both AD and PD 
[41, 42, 35]. More recently, spatial covariance studies using nAChR or mAChR 
ligands have been performed to explore cholinergic networks in the brain in AD 
and LBD.  
 Connectivity and network integrity appear to decrease in healthy aging, but 
this decrease is accelerated in AD, with specific systems hit hardest, such as the 
default mode network (DMN) [43]. The DMN is generally thought to include the 
posterior cingulate cortex/precuneus, medial prefrontal cortex, inferior parietal 
lobules, lateral temporal cortices, and hippocampus [44]. It has been proposed 
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that activity of this network during rest is necessary for memory consolidation 
[45]. 
 
Alzheimer disease  
 
 A spatial covariance study of M1/M4 mAChRs in AD using [123I]QNB 
SPECT  showed concomitant decreased uptake in medial temporal, inferior 
frontal, basal forebrain and cingulate relative to concomitant increased uptake in 
frontal poles, occipital, pre-post central and precuneus/superior parietal regions 
[46]. The relative pattern could suggest a loss of M1/M4 receptors in the medial 
temporal and cholinergic rich basal forebrain, accompanied by either 
preservation or an increase in cortical M1/M4 receptor availability. These 
changes thus may reflect a compensatory response to maintain basocortical 
cholinergic function given that loss of pre-synaptic receptors usually results in 
compensatory up-regulation of post-synaptic receptors [47]. The same group also 
reported a spatial covariance mapping study of α4β2 nicotinic receptors in AD 
using [123I]5IA-85380 SPECT. They found an α4β2 spatial covariance pattern 
characterized by relative decreases in α4β2 binding in basal forebrain, 
pedunculopontine, thalamus, limbic, parietal, and frontal regions together with 
relative preserved or increased binding in midbrain, pallidum, cerebellum, occipital, 
and pre/post central gyri [48]. The covariant pattern converged on various 
subcortical and neocortical regions, implicating a cholinergic network that mapped 
onto DMN hubs, namely, medial prefrontal, posterior cingulate, precuneus, and 
inferior parietal [48]. This was characterized by reduced cholinergic activity. The 
reduced DMN activity of nAChRs was consistent with the previously reported 
findings of reduced M1/M4 mAChR expressions within similar regions [46]. These 
observations highlight the potential role of both types of receptors in AD and the 
potentially more fundamental role of the cholinergic system in normal functioning 
of the DMN network. Interestingly, donepezil treatment has been reported to result 
in increased cerebral blood flow to the posterior cingulate cortex, a key node of the 
DMN, in patients with AD [49]. Other nAChR regions mapped onto established 
resting-state networks, included the anterior insula and anterior cingulate, which 
are key nodes of the “salience network”, for initiation of cognitive control and 
switching networks to aid access to working memory and attentional resources 
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[50]. Therefore, cholinergic deficits mediated through nAChR and mAChR 
receptors underlying cognition may occur within key brain networks in AD.   
 
Lewy body disorders 
  
 A spatial covariance pattern M1/M4 subtype mAChR brain [123I]QNB 
SPECT study in cholinesterase inhibitor drug naïve PD dementia patients versus 
control subjects found concomitant decreases in receptor in basal forebrain, 
temporal, striatal, insula, and anterior cingulate together with concomitant 
preserved or increases in frontal and parieto-occipital areas in the patients [51]. 
The mAChR pattern that donepezil treatment benefits overlapped with 
frontoparietal and default mode networks. Covariant preservation/upregulation in 
regions overlapping key nodes of the DMN and frontoparietal networks could imply 
that a relative cholinergic maintenance of these networks may be prerequisite for 
cognitive remediation following cholinergic treatment in PD dementia [51]. 
Interestingly, a α4β2 nAChR [123I]5IA SPECT study found evidence of not only 
reduced regional receptor binding (caudate nucleus, orbitofrontal cortex, and the 
middle temporal gyrus) but also higher binding in the putamen, insular cortex and 
the supplemental motor area in cognitively normal subjects with PD  [52]. Findings 
suggest evidence of upregulation in early stage of PD. Higher nAChR density may 
occur as a compensatory mechanism to maintain dopaminergic tone, in particular 
in the putamen and the supplemental motor regions, a key structure of the cortico-
basal ganglia motor loop [52]. 
 
MRI cholinergic basal forebrain volumetry studies 
 
 Complementary to molecular imaging techniques for assessing cholinergic 
denervation, volumetric analysis of the CBFB on high-resolution structural MRI 
scans is available as an in vivo surrogate measure of cholinergic degeneration in 
aging and neurodegenerative disease [53-55] that also allow assessment of 
cholinergic degeneration across different cholinergic brain forebrain subdivisions 
[56-59].  
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Normal aging, Alzheimer disease and Lewy body disorders: Evidence for early 
vulnerability of the cholinergic forebrain 
 
In vivo MRI volumetry studies confirm the relationship between CBFB with 
cognitive decline in AD and LBD [53, 54, 60, 61]. Unlike autopsy studies that are 
usually confined to relatively advanced disease stages, MRI-based CBFB 
volumetry has been particularly useful for studying the role of cholinergic forebrain 
degeneration for the emergence of cognitive impairments during preclinical and 
prodromal disease stages and their distinction from the normal aging process. For 
example, studies show that cholinergic forebrain structure is highly vulnerable to 
negative effects of physiologic aging, with annual atrophy rates of the CBFB being 
approximately three times higher than rates of global gray matter shrinkage even 
in cognitively stable healthy older individuals [53, 57]. This normal age-related 
CBFB degeneration is further accelerated in the presence of amyloid pathology, 
and increased AD-related CBFB degeneration can already be detected at 
completely asymptomatic disease stages [62-64]. 
The functional implications of these CBFB changes during normal aging 
and preclinical AD are still incompletely understood. The data implies that neither 
age-related, nor initial pathological degeneration of the CBFB are linked to 
clinically overt cognitive deficits. In clinically normal older individuals, CBFB 
volumes may only indirectly relate to neuropsychological test performance via 
more general factors such as level of education or intelligence [65, 66]. 
Alternatively, more detailed neuropsychological testing may be necessary to 
uncover relationships between subtle changes in cognitive performance and CBFB 
degeneration in non-clinical older populations. Indeed, in a study that directly 
measured source memory, an aspect of cognitive function disproportionately 
affected by the aging process [67], the relationship between CBFB volumes and 
performance was more evident  [68]. In vivo-measured CBFB degeneration was 
found to be robustly associated with declining cognition, particularly in the domains 
of memory and attentional function in early neurodegeneration such as MCI [59, 
66, 69]. 
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Multimodal cholinergic basal forebrain MRI volumetry and glucose metabolic PET 
imaging: Evidence for cholinergic mediated neural networks subserving memory 
and attention 
 
The effects of CBFB degeneration on cognitive impairments are likely 
mediated through cortical neuronal dysfunction that arises as a consequence of 
cholinergic depletion in the denervated cortical target areas [7]. The relation 
between CBFB degeneration, cortical dysfunction, and cognitive deficits can be 
studied in humans by combining MRI-based CBFB volumetry with detailed 
neuropsychometric evaluations and additional imaging modalities such as glucose 
metabolic PET for the assessment of cortical synaptic function. Using such a 
multimodal approach, it has been shown that in vivo CBFB degeneration in MCI is 
coupled with neuronal dysfunction in widespread cortical networks subserving 
memory and attentional processes, and that this association mediates the effect 
of CBFB degeneration on specific deficits in the respective cognitive domains [66]. 
For example, the effect of CBFB degeneration on episodic memory dysfunction 
was fully mediated by CBFB-associated hypometabolism in a cortical “memory” 
network spanning the hippocampus and retrosplenial/posterior cingulate cortex 
[70]. On the other hand, CBFB-associated hypometabolism in a distinct fronto-
temporo-parietal neocortical network accounted for the effect of CBFB 
degeneration on attentional control deficits. Such multimodal data therefore 
enables a better understanding of the role of CBFB degeneration in the cognitive 
sequelae of dementia syndromes [71], and could advance our knowledge of the 
mechanisms of cognition-enhancing cholinergic medications, thereby potentially 
helping to optimise their use as dementia treatments [72, 73]. For example, a 
randomized placebo-controlled trial of donepezil in MCI showed reduced rates of 
CBFB atrophy over 18 months compared with placebo. This effect was not 
reflected in a clinical effect of donepezil on episodic memory or executive function 
[74]. It remains to be shown in independent studies if these results indicate an 
impact of early cholinergic therapy on cholinergic system degeneration, and if 
volumetric measures may be more sensitive than classical neuropsychological 
tests for detecting treatment effects in the grey zone between symptomatic and 
disease modifying therapies. The coupling of multimodal datasets with the 
subregional anatomical specificity provided by automated volumetric 
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measurement of the CBFB could aid in advancing our understanding of brain 
stimulation interventions targeting the NBM, which are currently showing early 
promise for the treatment of cognitive impairments in AD and LBD [75, 71]. 
Importantly, such interventions may depend on the precise subregional targeting 
of the CBFB, but very little is known about its impact on the wider brain. 
Interestingly, we found that the observed structure-function-cognition 
relationships appeared to be independent of the presence of amyloid plaque 
pathology in AD as determined by PET imaging [66], indicating that the link 
between CBFB degeneration, cortical dysfunction, and cognitive impairment may 
not be specific for the prodromal phase of AD, but may similarly extend to other 
neurodegenerative disorders with CBFB involvement. While in vivo correlations 
between CBFB degeneration and dementia severity could already be 
demonstrated in LBD [53, 54, 60, 61], the course of CBFB degeneration during the 
predementia phase of these disorders and its relevance for the emergence of initial 
cognitive deficits remains to be studied in more detail [55, 76]. Interestingly, a 
longitudinal study of PD subjects with MCI demonstrated greater cholinergic 
forebrain loss in those converting to PD dementia [76].  
 
Discussion 
 
Local neural circuits and extended brain networks 
 
 The cholinergic system plays a key role in subserving cortical circuits 
underlying cognitive functioning [77]. Although the cholinergic system has more 
typically been viewed as both spatially and functionally ‘‘diffuse’’ [78], more recent 
mapping and morphological studies of basal forebrain cholinergic neurons 
demonstrate that these cholinergic projection neurons can be extremely elaborate 
in both the extent of axonal arbors and the number of axonal branches; there is 
topographic, rather than diffuse, organization of basal forebrain cholinergic 
neurons and their target fields forming topographically distinct circuits [79]. 
 Cholinergic receptor studies show that cortical cholinergic changes in AD 
and DLB are not diffuse but have topographic vulnerability that overlap with 
important hubs of neural more extended networks involved in various cognitive 
functions [46, 51, 48]. Bidirectional changes in regional cerebral cholinergic 
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receptor expression may reflect the effects of neural function losses in some 
regions and compensatory responses in other brain areas.  Multimodal MRI 
CBFB volumetry and glucose metabolic PET studies have also identified distinct 
neural network correlates of impaired episodic memory and attention in AD [66].  
 
Revisiting the cholinergic hypothesis of dementia 
 
 Interest toward the cholinergic hypothesis in AD has considerably 
decreased over the last few decades, mostly because of the poor efficacy of the 
current AChE inhibitor treatments [8]. Our previous AChE PET imaging and 
donepezil treatment study in AD showed limited and modest donepezil-induced 
cerebral enzyme inhibition in AD [80].  Therefore, lack of efficacy of cholinergic 
augmentation therapy due to suboptimal brain effects is not a valid argument to 
discount the cholinergic hypothesis of dementia. Conceivably, novel centrally more 
active cholinergic pharmacotherapies may potentially result in clinically more 
meaningful effects. Interestingly, more recent pharmacological support for the 
cholinergic hypothesis of dementia comes from the accumulating evidence of 
striking cognitive side-effects and acceleration of cognitive decline in the elderly 
due to anti-cholinergic side-effect burden of commonly used medications. For 
example, a recent study found that anti-cholinergic drug burden was associated 
with memory and executive function deficits, greater cortical atrophy and reduced 
temporal lobe cortical thickness and greater clinical decline in the elderly [81]. 
 It is also clear that there are multiple layers of pathobiological mechanism 
underlying dementia (Figure 1) and that a single component of this multifactorial 
system cannot account for the complete dementia syndrome. As such, the 
cholinergic system is one among others that when it fails it may exacerbate 
cognitive deficits and worsens the severity of dementia [7].  
 
-- Insert figure 1 about here. 
 
 Recent advances in neuroimaging show that the cholinergic hypothesis is 
evolving from a primary focus of the effect of cholinergic loss on memory toward a 
more complex systems interaction with other neurodegenerations in AD and LBD. 
Cortical cholinergic denervation is a major neurodegeneration associated with 
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progressive declines across the spectrum of cognitive impairment in PD and 
typically occurs in the context of significant caudate nucleus dopaminergic 
denervation [33]. Cholinergic-dopaminergic interactions support the so-called 
'compensatory' hypothesis where dual neurotransmitter system losses may 
aggravate cognitive, esp. executive function, deficits and jointly increase the risk 
of conversion to dementia in PD [33]. Conversely, fronto-parietal cortical 
cholinergic functions associated with top-down control may be recruited (increased 
cholinergic activity in cortical circuits) to compensate for executive dysfunctions 
associated with striatal dopaminergic declines in early stage disease (Table 1). 
 
-- Insert Table 1 about here. 
 
 Cholinergic system changes are more complex in LBD because of 
additional subcortical cholinergic changes including the basal ganglia, thalamus 
and cerebellum [31] that are relatively spared in AD [21, 25]. Thalamic cholinergic 
hypofunction is selectively associated with bottom-up salience functions in PD [38]. 
Cholinergic system changes also play a role in cognition-dependent mobility 
functions, such as slow gait speed or falls [82, 83].  
 Cholinergic systems appear to enable adaptation to injury even as they 
degenerate, which has implications for functional restoration [69]. For example, a 
post-mortem study found evidence of cholinergic plasticity in the hippocampus in 
patients with MCI with a significant elevation of hippocampal choline acetyl 
transferase activity that may reflect a compensatory response to the progressive 
denervation of the hippocampus by lost entorhinal cortex input [84]. Cholinergic 
signaling - at least in the setting of preserved cholinergic nerve terminals - may 
enable a compensatory effect to preserve cognitive functions in the setting of non-
cholinergic pathology in dementia, like Lewy bodies or dopaminergic losses in PD 
or proteineopathies in AD. Therefore, preserving the integrity of upregulated 
compensatory cholinergic brain regions may provide novel treatment strategies.   
 
Conclusions 
 
 Recent neuroimaging work provides compelling evidence that the loss of 
cholinergic system integrity and cognitive decline are intrinsically linked in AD and 
   17 
LBD. It is evident that loss of cholinergic neurons enhances the severity of the 
symptoms of dementia. This is supported by new insights that the integrity of 
cholinergic nerve terminals may modulate brain networks subserving various 
cognitive functions. Cholinergic system changes are more complex in LBD 
because of additional subcortical degenerations compared to AD, where 
subcortical cholinergic changes may associate with bottom-up salience attentional 
functions. Further elucidation of possible compensatory functions of cholinergic 
nerve terminals in the setting of other pathologies in neurodegeneration may have 
important implication for novel functional restoration approaches. Invasive and 
non-invasive neuromodulation stimulation approaches may selectively target 
cholinergic-dependent circuits or network functions. Similarly as shown by the 
successful dopaminergic replacement therapy for PD, more centrally active and 
effective cholinergic augmentation therapy could make a substantial clinical impact 
and may help to revive the cholinergic hypothesis of dementia, which has become 
more multifaceted with regional, bidirectional and disease-specific changes. In this 
respect, a personalized medicine approach may be prudent to maximize 
enhancement and minimize impairments of cholinergic treatments. 
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Table 2 Take-home messages  
 
- Loss of cholinergic neurons enhances the severity of the symptoms of 
dementia and may result from loss of cholinergic maintenance of neural 
networks subserving various cognitive functions.  
- Vulnerability of the cholinergic forebrain may already occur in preclinical and 
prodromal stages of neurodegeneration 
- Bidirectional changes in regional cerebral cholinergic receptor expression may 
reflect in part the effects of neural function losses in some regions and 
compensatory responses to maintain cholinergic function in other brain areas 
- Multiplicative effects between cholinergic and dopaminergic losses may 
significantly contribute to dementia risk in PD 
- Cholinergic system changes are more extensive in Lewy body disorders 
because of subcortical cholinergic degenerations that are relatively spared in 
AD. 
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Figure legend: 
 
Figure 1 
 
Diagram showing the multiple layers of pathobiological mechanisms underlying 
dementia. Cholinergic neurotransmitter changes occur at the neuronal level but 
the long axonal projections will affect regional cerebral circuits and network 
functions. 
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Table 1.  
 
Simplified model of dopaminergic and cholinergic interaction effects and cognition 
in PD illustration the compensatory hypothesis. This hypothesis is based on the 
observation that a substantial proportion of patients with no apparent cognitive 
deficits, including on executive tasks, nevertheless had significant dopaminergic 
denervation in the setting of preserved cholinergic activity. In other words, fronto-
parietal cortical cholinergic functions associated with top-down control may be 
recruited (increased cholinergic activity in cortical circuits) to compensate for 
executive dysfunctions associated with striatal dopaminergic declines, and vice 
versa.  
 
 
Dopaminergic system Cholinergic system Cognition 
 Preserved to increased 
Attenuation or masking 
of cognitive deficits, esp. 
executive function 
deficits 
  
Exacerbation of 
cognitive deficits, esp. 
executive function 
deficits 
 
 
 
 
 
 
 
 
 
 
 
